MK-677: Common Questions and What the Literature Says

MK-677, also written MK-0677 and commonly called ibutamoren, is an orally active growth hormone secretagogue that acts as a ghrelin receptor agonist. It has been studied in humans, rodents and horses, but the indexed literature remains small, and several of the questions people search most often have never been the subject of a published study. This page summarises what researchers actually reported, and states plainly where no study exists. This page is for educational purposes only and is not medical advice; consult a licensed physician about any health decision. It is also not legal advice.

Question-by-question: what the literature does and does not cover

What MK-677 is, as described in the studies

Across the indexed papers, MK-677 is characterised as an orally active growth hormone secretagogue. In an animal model of Alzheimer's disease, researchers described MK-0677 as a ghrelin agonist and reported that it alleviated amyloid beta-related pathology in 5XFAD mice (PMID 29912176). A separate rodent study examined the effect of the orally active growth hormone secretagogue MK-677 on somatic growth in rats, and the study was framed around whether stimulating the growth hormone axis orally altered growth outcomes (PMID 30450851).

MK-677 is not an approved medicine in the United States. Compounds of this class circulate as research chemicals and are frequently labelled for research use only. That regulatory status is a fact about product labelling, not a statement about safety or effectiveness.

Does MK-677 show up on a drug test? What the literature reports

This is the most searched question on the topic, and the honest answer from the indexed literature is that no published human study was located that tested whether MK-677 is detected by routine urine drug-screening panels. Routine immunoassay panels are designed around specific target classes, and a compound is generally only detected when an assay or confirmatory method has been validated for it. No paper in the verified set validated such a method in humans.

The closest published work is analytical rather than clinical. Researchers reported detection of the growth hormone secretagogue MK-0677 in equine hair following oral administration, using targeted analytical chemistry rather than a general screening panel (PMID 36354265). That study establishes that the parent compound can be recovered from a keratin matrix after oral dosing in horses when laboratories are specifically looking for it. It does not establish detection windows in humans, does not describe urine testing, and does not describe any workplace or military panel.

Military drug testing specifically

No study in the verified literature examined military drug-testing programmes, their panels, or MK-677. Anything written online asserting a specific outcome for a military urinalysis is not supported by an indexed study. Readers with an occupational or service obligation generally look to the governing testing policy and their own command or employer, not to the pharmacology literature, because whether a substance is screened for is a policy and laboratory-method question rather than a scientific one. Anti-doping laboratories in sport have historically treated growth hormone secretagogues as a targeted class, which is why the equine hair method described above was developed at all (PMID 36354265).

Timing of administration: what trials actually used

Searches about the "best time" for MK-677 assume that a comparative study exists. None was located. No published trial in the verified set randomised participants to morning versus evening administration, compared fasted with fed administration, or measured whether timing altered outcomes. Statements circulating in forums about night-time administration and sleep architecture are not drawn from any study in this set.

What the literature does describe is the schedule used inside one clinical trial. In a 12-month randomised trial in patients with mild-to-moderate Alzheimer's disease, researchers administered oral MK-677 at 25 mg once daily and reported no clinical effect on disease progression compared with placebo (PMID 19015485). That was a once-daily oral regimen selected by the investigators for a specific research question in an older clinical population. It is a description of a study protocol, not a schedule for anyone outside that trial, and the study's primary finding was negative for the disease endpoint it tested.

The rodent literature similarly describes oral administration without answering timing questions. The rat study on somatic growth was designed to assess growth outcomes from oral secretagogue exposure, not to compare administration times (PMID 30450851).

Alcohol and MK-677: no published interaction data

No study in the verified literature examined alcohol consumption alongside MK-677 in humans or animals. There is no pharmacokinetic interaction study, no hepatic safety study involving co-exposure, and no clinical observation series on the combination. Any confident claim about the pairing is unsupported by the indexed record.

What is relevant context is that the liver has already appeared in the MK-677 safety literature. A 2025 BMJ Case Reports paper described hepatotoxicity induced by MK-677 in a single patient (PMID 40675653). A case report describes one person and cannot establish how often liver injury occurs or in whom, but it is the reason clinicians discussing this compound raise hepatic monitoring at all. Because alcohol is itself hepatotoxic and no study has characterised combined exposure, the literature simply does not support a statement in either direction.

Adverse Events: What Studies Report

The adverse-event literature for MK-677 is thin and comes from three directions: a controlled trial, a case report of harm, and a self-reported use case report.

• Hepatotoxicity. The 2025 case report documented liver injury attributed to MK-677 use and was published precisely because the association had not been widely described (PMID 40675653). Single cases cannot establish incidence.
• Clinical trial outcome. In the 12-month Alzheimer's trial, researchers reported that MK-677 produced no clinical effect on disease progression, which is a negative efficacy finding rather than an adverse-event finding (PMID 19015485).
• Combined-use case report. A 2022 case report in Experimental Physiology followed one individual using LGD-4033 and MK-677 and reported changes in body composition, circulating biomarkers, and skeletal muscle androgenic hormone and receptor content (PMID 36303408). Because two compounds were used together in a single person, the study could not attribute any individual change to MK-677 alone.

Nothing in the verified set quantifies the frequency of adverse events in people using MK-677 outside of clinical supervision, because no cohort study of that population was located.

What the animal literature reports

Two animal papers make up much of the mechanistic record. The rat study assessed the effect of orally active MK-677 on somatic growth, consistent with the compound's characterisation as a growth hormone secretagogue (PMID 30450851). In 5XFAD mice, an established model of Alzheimer's disease, researchers reported that MK-0677 alleviated amyloid beta-related pathology (PMID 29912176).

The tension between the mouse result and the human trial is instructive. A positive pathology signal in a transgenic mouse model did not translate into a clinical benefit when the compound was tested over 12 months in patients with mild-to-moderate Alzheimer's disease (PMID 19015485). That pattern — promising preclinical pathology findings followed by a negative clinical endpoint — is common in the field and is a reason animal findings are not read as human outcomes.

Where the evidence gaps sit

1. Human detection windows. No indexed human study of urine, blood or hair detection was located; the only detection paper involved horses (PMID 36354265).
2. Timing comparisons. No study compared administration times or meal states.
3. Alcohol or other co-exposures. No interaction study exists in the verified set.
4. Long-term safety in healthy adults. The longest human study located was a 12-month trial in an older patient population with Alzheimer's disease (PMID 19015485), not in healthy younger adults.
5. Attribution in combined use. The one physiology case report involved two compounds at once, limiting what could be attributed to either (PMID 36303408).

Readers evaluating online claims about MK-677 may find it useful to ask which of these five gaps a given claim would have to fill, and whether a citation is offered that fills it. In the verified literature reviewed here, most popular claims fall into gaps rather than into findings.

References

• Hepatotoxicity induced by MK-677 (BMJ Case Reports, 2025)
• LGD-4033 and MK-677 use impacts body composition, circulating biomarkers, and skeletal muscle androgenic hormone and receptor content: A case report (Experimental Physiology, 2022)
• Effect of the Orally Active Growth Hormone Secretagogue MK-677 on Somatic Growth in Rats (Yonsei Medical Journal, 2018)
• Detection of the growth hormone secretagogue MK-0677 in equine hair following oral administration (Drug Testing and Analysis, 2023)
• Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial (Neurology, 2008)
• MK-0677, a Ghrelin Agonist, Alleviates Amyloid Beta-Related Pathology in 5XFAD Mice, an Animal Model of Alzheimer's Disease (International Journal of Molecular Sciences, 2018)